Autologous IL2 and CD40 ligand-expressing tumor cells (Baylor College of Medicine)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAutologous IL2 and CD40 ligand-expressing tumor cells (Baylor College of Medicine)
Drug Alias NameN/A
ClassificationVaccines > Application > Therapeutic vaccine
Mechanisms of ActionTumor necrosis factor receptor superfamily member 5 inhibitors
TargetsTumor necrosis factor receptor superfamily member 5
Therapy Area/IndicationsLeukemia, Lymphocytic, Chronic, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesBaylor College Of Medicine
China Registration ClassN/A

Develop Information

Active CompaniesBaylor College Of Medicine
Inactive CompaniesN/A
Active IndicationsLeukemia, Lymphocytic, Chronic, B-Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A